The effect of probiotics on inflammatory bowel disease Remission and relaps rate: A systematic review and meta-analysis

Louis Edwin  Wirya; Heinz Purwadi Gunawan  Schoeck; Epistel Pangujian  Simatupang

doi:10.36216/jpd.v8i1.240

Authors

Louis Edwin Wirya Department of Internal Medicine Siloam Hospitals Kebon Jeruk, Jakarta
Heinz Purwadi Gunawan Schoeck Department of Internal Medicine Prof. Dr. IGNG Ngoerah Hospitals, Denpasar ; Division of Gastroenterohepatologi Siloam Hospitals Kebon Jeruk, Jakarta
Epistel Pangujian Simatupang Department of Internal Medicine Siloam Hospitals Kebon Jeruk, Jakarta

DOI:

https://doi.org/10.36216/jpd.v8i1.240

Keywords:

Probiotic, Inflammatory Bowel Disease , Remission, Relapse

Abstract

Introduction: Dysbiosis is believed to play a role in the pathogenesis of Inflammatory Bowel Disease (IBD). Therefore, there is a hope that giving probiotics can be an addition to standard IBD treatment. This study aims to examine the efficacy of probiotics on the remission and relapse rates of IBD and its safety profile.

Methods: The authors collected studies from PubMed, Scopus, Embase, Cochrane, and Google Scholar. Inclusion criteria included all randomized controlled trials that compared groups of adult IBD patients (>18 years) who received probiotics and placebo on their standard treatment.

Results: Twenty-four studies met the inclusion criteria with a total sample of 2,233. The mean age of the sample was 39.1 ± 12.4 years in the probiotic group and 38.2 ± 12.3 years in the placebo group. The remission rate in the probiotic group was higher than placebo (OR 1.58, 95% CI 1.28-1.95, p<0.0001). Moreover, the relapse rate in the probiotic group was significantly lower than in the placebo group (OR 0.70 CI 95% 0.53-0.93, p=0.01). There was no significant difference in the incidence of adverse events in the probiotic group compared to placebo (RR 1.04, CI 95% 0.85-1.29, p=0.68). Multistrain probiotics increased the remission rate(OR 2.68, CI 95% 1.88 -3.83, p=<0.00001). Meanwhile, only Bifidobacterium sp. significantly reduced the relapse rate (OR 0.07, p=0.002).

Conclusion: Probiotics can significantly ameliorate the remission rate and reduce the relapse rate in IBD patients. Giving probiotics that contain particular strains can increase the remission rate and reduce the relapse rate in IBD.

Downloads

Download data is not yet available.

Author Biographies

Louis Edwin Wirya, Department of Internal Medicine Siloam Hospitals Kebon Jeruk, Jakarta

Department of Internal Medicine Siloam Hospitals Kebon Jeruk, Jakarta
Heinz Purwadi Gunawan Schoeck, Department of Internal Medicine Prof. Dr. IGNG Ngoerah Hospitals, Denpasar ; Division of Gastroenterohepatologi Siloam Hospitals Kebon Jeruk, Jakarta

Department of Internal Medicine Prof. Dr. IGNG Ngoerah Hospitals, Denpasar ;

Division of Gastroenterohepatologi Siloam Hospitals Kebon Jeruk, Jakarta
Epistel Pangujian Simatupang, Department of Internal Medicine Siloam Hospitals Kebon Jeruk, Jakarta

Department of Internal Medicine Siloam Hospitals Kebon Jeruk, Jakarta

References

Liu, S, et al. The Microbiome in Inflammatory Bowel Diseases: From Pathogenesis to Therapy. Protein Cell 2021, 12(5):331–345

Santana PT, Rosas SLB, Ribeiro BE, Marinho Y, de Souza HSP. 2022. Dysbiosis in Inflammatory Bowel Disease: Pathogenic Role and Potential Therapeutic Targets. Int J Mol Sci. 2022 Mar 23;23(7):3464

Shaw, K.A., Bertha, M., Hofmekler, T. et al. Dysbiosis, Inflammation, and Response to Treatment: a Longitudinal Study of Pediatric Subjects with Newly Diagnosed Inflammatory Bowel Disease. Genome Med 8, 75

Tamboli CP, Neut C, Desreumaux P, Colombel JF. Dysbiosis in Inflammatory Bowel Disease. Gut. 2004 Jan;53(1):1-4

Yu, L.CH. 2018. Microbiota Dysbiosis and Barrier Dysfunction in Inflammatory Bowel Disease and Colorectal Cancers: Exploring a Common Ground Hypothesis. J Biomed Sci 25, 79

Fan H, Du J, Liu X, Zheng WW, Zhuang ZH, Wang CD, Gao R. Effects of pentasa-combined probiotics on the microflora structure and prognosis of patients with inflammatory bowel disease. Turk J Gastroenterol. 2019 Aug;30(8):680-685

Torres, J., Mehandru, S., Colombel, J.-F., & Peyrin-Biroulet, L. (2017). Crohn’s disease. The Lancet, 389(10080), 1741–1755.

Wildt S, Nordgaard I, Hansen U, Brockmann E, Rumessen JJ. A randomised double-blind placebo-controlled trial with Lactobacillus acidophilus La-5 and Bifidobacterium animalis subsp. lactis BB-12 for maintenance of remission in ulcerative colitis. J Crohns Colitis. 2011 Apr;5(2):115-21

Matsuoka K, Uemura Y, Kanai T, Kunisaki R, Suzuki Y, Yokoyama K, Yoshimura N, Hibi T. Efficacy of Bifidobacterium breve Fermented Milk in Maintaining Remission of Ulcerative Colitis. Dig Dis Sci. 2018 Jul;63(7):1910-1919

Bourreille A, Cadiot G, Le Dreau G, Laharie D, Beaugerie L, Dupas JL, Marteau P, Rampal P, Moyse D, Saleh A, Le Guern ME, Galmiche JP; FLORABEST Study Group. Saccharomyces boulardii does not prevent relapse of Crohn's disease. Clin Gastroenterol Hepatol. 2013 Aug;11(8):982-7

Kamarli Altun H, Akal Yildiz E, Akin M. Impact of Synbiotic Therapy on the Quality of Life in Patients with Mild-to-Moderately Active Ulcerative Colitis. J Gastrointestin Liver Dis. 2022 Dec 17;31(4):417-423

Park SK, Kang SB, Kim S, Kim TO, Cha JM, Im JP, Choi CH, Kim ES, Seo GS, Eun CS, Han DS, Park DI. Additive effect of probiotics (Mutaflor) on 5-aminosalicylic acid therapy in patients with ulcerative colitis. Korean J Intern Med. 2022 Sep;37(5):949-957

Fedorak RN, Feagan BG, Hotte N, Leddin D, Dieleman LA, Petrunia DM, Enns R, Bitton A, Chiba N, Paré P, Rostom A, Marshall J, Depew W, Bernstein CN, Panaccione R, Aumais G, Steinhart AH, Cockeram A, Bailey RJ, Gionchetti P, Wong C, Madsen K. The probiotic VSL#3 has anti-inflammatory effects and could reduce endoscopic recurrence after surgery for Crohn's disease. Clin Gastroenterol Hepatol. 2015 May;13(5):928-35.e2

Bjarnason I, Sission G, Hayee B. A randomised, double-blind, placebo-controlled trial of a multi-strain probiotic in patients with asymptomatic ulcerative colitis and Crohn's disease. Inflammopharmacology. 2019 Jun;27(3):465-473

Kruis W, Fric P, Pokrotnieks J, Lukás M, Fixa B, Kascák M, Kamm MA, Weismueller J, Beglinger C, Stolte M, Wolff C, Schulze J. Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine. Gut. 2004 Nov;53(11):1617-23

Yoshimatsu Y, Yamada A, Furukawa R, Sono K, Osamura A, Nakamura K, Aoki H, Tsuda Y, Hosoe N, Takada N, Suzuki Y. Effectiveness of probiotic therapy for the prevention of relapse in patients with inactive ulcerative colitis. World J Gastroenterol. 2015 May 21;21(19):5985-94

Schultz M, Timmer A, Herfarth HH, Sartor RB, Vanderhoof JA, Rath HC. Lactobacillus GG in inducing and maintaining remission of Crohn's disease. BMC Gastroenterol. 2004 Mar 15;4:5

Sood A, Midha V, Makharia GK, Ahuja V, Singal D, Goswami P, Tandon RK. The probiotic preparation, VSL#3 induces remission in patients with mild-to-moderately active ulcerative colitis. Clin Gastroenterol Hepatol. 2009 Nov;7(11):1202-9, 1209.e1

Petersen AM, Mirsepasi H, Halkjær SI, Mortensen EM, Nordgaard-Lassen I, Krogfelt KA. Ciprofloxacin and probiotic Escherichia coli Nissle add-on treatment in active ulcerative colitis: a double-blind randomized placebo controlled clinical trial. J Crohns Colitis. 2014 Nov;8(11):1498-505

Guslandi M, Mezzi G, Sorghi M, Testoni PA. Saccharomyces boulardii in maintenance treatment of Crohn's disease. Dig Dis Sci. 2000 Jul;45(7):1462-4

Tamaki H, Nakase H, Inoue S, Kawanami C, Itani T, Ohana M, Kusaka T, Uose S, Hisatsune H, Tojo M, Noda T, Arasawa S, Izuta M, Kubo A, Ogawa C, Matsunaka T, Shibatouge M. Efficacy of probiotic treatment with Bifidobacterium longum 536 for induction of remission in active ulcerative colitis: A randomized, double-blinded, placebo-controlled multicenter trial. Dig Endosc. 2016 Jan;28(1):67-74

Matthes H, Krummenerl T, Giensch M, Wolff C, Schulze J. Clinical trial: probiotic treatment of acute distal ulcerative colitis with rectally administered Escherichia coli Nissle 1917 (EcN). BMC Complement Altern Med. 2010 Apr 15;10:13

Zocco MA, dal Verme LZ, Cremonini F, Piscaglia AC, Nista EC, Candelli M, Novi M, Rigante D, Cazzato IA, Ojetti V, Armuzzi A, Gasbarrini G, Gasbarrini A. Efficacy of Lactobacillus GG in maintaining remission of ulcerative colitis. Aliment Pharmacol Ther. 2006 Jun 1;23(11):1567-74

Tursi A, Brandimarte G, Giorgetti GM, Forti G, Modeo ME, Gigliobianco A. Low-dose balsalazide plus a high-potency probiotic preparation is more effective than balsalazide alone or mesalazine in the treatment of acute mild-to-moderate ulcerative colitis. Med Sci Monit. 2004 Nov;10(11)

Kato K, Mizuno S, Umesaki Y, Ishii Y, Sugitani M, Imaoka A, Otsuka M, Hasunuma O, Kurihara R, Iwasaki A, Arakawa Y. Randomized placebo-controlled trial assessing the effect of bifidobacteria-fermented milk on active ulcerative colitis. Aliment Pharmacol Ther. 2004 Nov 15;20(10):1133-41

Rembacken BJ, Snelling AM, Hawkey PM, Chalmers DM, Axon AT. Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial. Lancet. 1999 Aug 21;354(9179):635-9

Prantera C, Scribano ML, Falasco G, Andreoli A, Luzi C. Ineffectiveness of probiotics in preventing recurrence after curative resection for Crohn's disease: a randomised controlled trial with Lactobacillus GG. Gut. 2002 Sep;51(3):405-9

Kruis W, Schütz E, Fric P, Fixa B, Judmaier G, Stolte M. Double-blind comparison of an oral Escherichia coli preparation and mesalazine in maintaining remission of ulcerative colitis. Aliment Pharmacol Ther. 1997 Oct;11(5):853-8

Tursi A, Brandimarte G, Papa A, Giglio A, Elisei W, Giorgetti GM, Forti G, Morini S, Hassan C, Pistoia MA, Modeo ME, Rodino' S, D'Amico T, Sebkova L, Sacca' N, Di Giulio E, Luzza F, Imeneo M, Larussa T, Di Rosa S, Annese V, Danese S, Gasbarrini A. Treatment of relapsing mild-to-moderate ulcerative colitis with the probiotic VSL#3 as adjunctive to a standard pharmaceutical treatment: a double-blind, randomized, placebo-controlled study. Am J Gastroenterol. 2010 Oct;105(10):2218-27

Ishikawa H, Akedo I, Umesaki Y, Tanaka R, Imaoka A, Otani T. Randomized controlled trial of the effect of bifidobacteria-fermented milk on ulcerative colitis. J Am Coll Nutr. 2003 Feb;22(1):56-63